MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a naturally occurring 16-amino acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome rather than the cell’s nuclear DNA. It was first identified in 2015 and is one of a small group of mitochondrial peptides believed to function as signaling molecules that help regulate cellular metabolism, energy production, and adaptation to metabolic stress.
Unlike most therapeutic peptides, MOTS-c is produced from mitochondrial DNA and acts as an endocrine-like signaling molecule. Research suggests it plays an important role in glucose metabolism, insulin sensitivity, exercise adaptation, aging, and mitochondrial homeostasis. Circulating MOTS-c levels appear to decline with age, and exercise has been shown to transiently increase endogenous MOTS-c concentrations in humans.
Although MOTS-c has generated significant scientific interest, it remains investigational and is not FDA-approved for any medical indication in the United States.
MOTS-c functions as a metabolic signaling peptide that helps cells adapt to energy stress.
Current research suggests MOTS-c may:
During metabolic stress, MOTS-c can translocate from the mitochondria to the nucleus, where it influences the expression of genes involved in stress resistance and metabolic regulation. This unique mechanism distinguishes it from most peptide hormones.
Published research suggests MOTS-c may have several biologic effects, although much of the evidence comes from laboratory and animal studies.
Potential benefits may include:
Exercise studies have shown that endogenous MOTS-c levels increase following physical activity, suggesting that it may play an important role in exercise-mediated metabolic adaptation. Human observational studies have also reported associations between circulating MOTS-c levels and metabolic health, although causation has not been established.
Because MOTS-c remains investigational, its long-term safety profile in humans has not been fully established.
Potential adverse effects may include:
Because MOTS-c influences glucose metabolism, patients with diabetes or those taking glucose-lowering medications should be monitored carefully if participating in clinical research. Current human safety data remain limited.
Because no FDA-approved prescribing information exists, formal contraindications have not been established. Based on current knowledge, MOTS-c should generally be avoided or used only with specialist supervision in individuals with:
Patients with chronic metabolic disease should be evaluated and monitored by a qualified healthcare provider before considering investigational peptide therapies.
MOTS-c is NOT FDA-approved for any medical indication in the United States.
It is not FDA-approved for:
MOTS-c continues to be investigated in clinical trials evaluating insulin sensitivity and cardiometabolic health, but no approved therapeutic indication currently exists.
Human Studies
Human research on MOTS-c remains relatively limited but is growing.
Published studies have shown:
Animal & Preclinical Studies
Most evidence supporting MOTS-c comes from laboratory and animal research.
Animal studies have demonstrated that MOTS-c may:
These findings provide biologic plausibility but do not establish safety or effectiveness for clinical use in humans.
Human Studies
Animal & Preclinical Studies
Review Articles
Regulatory Resources
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information.
MOTS-c is not FDA-approved for any medical indication in the United States. Current evidence consists primarily of laboratory studies, animal research, observational human data, and early-phase clinical trials. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# SS-31 (Elamipretide)